Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies

Détails

ID Serval
serval:BIB_04D7294A51E7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies
Périodique
Proc Natl Acad Sci U S A
Auteur⸱e⸱s
Kabanova A., Perez L., Lilleri D., Marcandalli J., Agatic G., Becattini S., Preite S., Fuschillo D., Percivalle E., Sallusto F., Gerna G., Corti D., Lanzavecchia A.
ISSN
0027-8424 (Print)
0027-8424
Statut éditorial
Publié
Date de publication
2014
Volume
111
Numéro
50
Pages
17965-70
Langue
anglais
Notes
1091-6490
Kabanova, Anna
Perez, Laurent
Lilleri, Daniele
Marcandalli, Jessica
Agatic, Gloria
Becattini, Simone
Preite, Silvia
Fuschillo, Dario
Percivalle, Elena
Sallusto, Federica
Gerna, Giuseppe
Corti, Davide
Lanzavecchia, Antonio
Journal Article
Research Support, Non-U.S. Gov't
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17965-70. doi: 10.1073/pnas.1415310111. Epub 2014 Dec 1.
Résumé
The use of neutralizing antibodies to identify the most effective antigen has been proposed as a strategy to design vaccines capable of eliciting protective B-cell immunity. In this study, we analyzed the human antibody response to cytomegalovirus (human cytomegalovirus, HCMV) infection and found that antibodies to glycoprotein (g)B, a surface glycoprotein that has been developed as a HCMV vaccine, were primarily nonneutralizing. In contrast, most of the antibodies to the complex formed by gH, gL, protein (p)UL128, pUL130, and pUL131 (the gHgLpUL128L pentamer) neutralized HCMV infection with high potency. Based on this analysis, we developed a single polycistronic vector encoding the five pentamer genes separated by "self-cleaving" 2A peptides to generate a stably transfected CHO cell line constitutively secreting high levels of recombinant pentamer that displayed the functional antigenic sites targeted by human neutralizing antibodies. Immunization of mice with the pentamer formulated with different adjuvants elicited HCMV neutralizing antibody titers that persisted to high levels over time and that were a hundred- to thousand-fold higher than those found in individuals that recovered from primary HCMV infection. Sera from mice immunized with the pentamer vaccine neutralized infection of both epithelial cells and fibroblasts and prevented cell-to-cell spread and viral dissemination from endothelial cells to leukocytes. Neutralizing monoclonal antibodies from immunized mice showed the same potency as human antibodies and targeted the same as well as additional sites on the pentamer. These results illustrate with a relevant example a general and practical approach of analytic vaccinology for the development of subunit vaccines against complex pathogens.
Mots-clé
Animals, Antibodies, Monoclonal/immunology, Antibodies, Neutralizing/*immunology, Antigens, Viral/*immunology/isolation & purification, CHO Cells, Cricetinae, Cricetulus, Cytomegalovirus Vaccines/*immunology, *Drug Design, Enzyme-Linked Immunosorbent Assay, Genetic Vectors/genetics, HEK293 Cells, Humans, Mice, Statistics, Nonparametric, Vaccines, Subunit/immunology, analytic vaccinology, human cytomegalovirus, vaccine, F.S. and A.L. hold shares in Humabs BioMed SA. G.A. and D.C. are employees of Humabs, Biomed, a commercial company that might like to commercialize this technological, approach.
Création de la notice
04/09/2020 20:03
Dernière modification de la notice
07/09/2020 6:26
Données d'usage